List of Determinations Including Written Request

Why It Matters

Pediatric exclusivity extensions boost revenue and incentivize pediatric research, shaping drug development strategies across the industry. Transparency of these grants helps investors assess pipeline value and regulatory risk.

Key Takeaways

• FDA tracks 189 pediatric exclusivity grants since 2007
• Grants add six months market protection for pediatric studies
• Sponsors must submit written requests and amendments to qualify
• List aids transparency for investors and healthcare stakeholders
• Determinations influence drug development pipelines and pricing strategies

Pulse Analysis

The pediatric exclusivity program, established by the Best Pharmaceuticals for Children Act and reinforced by the FDA Amendments Act, grants an additional six months of market protection to sponsors who conduct FDA‑mandated studies in children. By filing a Written Request that outlines the proposed pediatric study plan, companies can secure this extension, provided the studies meet regulatory standards. The FDA’s public ledger of determinations serves as a compliance checkpoint, ensuring that only qualified products benefit from the exclusivity and that the data supporting pediatric use are publicly accessible.

For pharmaceutical firms, the exclusivity extension represents a valuable financial incentive. The six‑month period can translate into millions of dollars in additional revenue, especially for high‑margin biologics and specialty drugs. Consequently, sponsors often prioritize pediatric study designs that align with the Written Request requirements, integrating them early in the drug development timeline. Investors monitor the FDA’s determinations closely, as a new exclusivity grant can enhance a company’s pipeline valuation and affect competitive dynamics within therapeutic categories such as oncology, antivirals, and chronic disease treatments.

Looking ahead, the FDA is likely to refine its pediatric exclusivity criteria to address emerging therapeutic modalities, including gene therapies and digital health interventions. Greater emphasis on real‑world evidence and diverse patient populations may reshape the content of future Written Requests. Stakeholders—ranging from drug developers to policy analysts—should watch the evolving list for signals about regulatory focus areas and potential market opportunities, as transparency in pediatric exclusivity continues to influence strategic planning and investment decisions.